María José Casanova, Cristina Rubín de Célix, Sabino Riestra, Alfredo J. Lucendo, José Manuel Benítez, Mercè Navarro-Llavat, Jesús Barrio, Víctor J. Morales-Alvarado, Montserrat Rivero, David Busquets, Eduardo Leo-Carnerero, Oscar Nantes-Castillejo, Pablo Navarro, Manuel Van Domselaar, Ana Gutiérrez-Casbas, Inmaculada Alonso-Abreu, Manuel Barreiro-de Acosta, Luis Fernández-Salazar, Marisa Iborra, María Dolores Martín-Arranz, Natalia García-Morales, Jordi Guardiola, Abdel Bouhmidi-Assakali, María Esteve, Carmen Muñoz-Villafranca, Iago Rodríguez-Lago, Daniel Ceballos, Iván Guerra, Miriam Mañosa, Ignacio Marín-Jiménez, Isabel Vera-Mendoza, Ana Garre, María Chaparro, Javier P. Gisbert
{"title":"炎症性肠病患者在缓解期停止抗肿瘤坏死因子治疗后的长期结果：GETECCU的长期研究","authors":"María José Casanova, Cristina Rubín de Célix, Sabino Riestra, Alfredo J. Lucendo, José Manuel Benítez, Mercè Navarro-Llavat, Jesús Barrio, Víctor J. Morales-Alvarado, Montserrat Rivero, David Busquets, Eduardo Leo-Carnerero, Oscar Nantes-Castillejo, Pablo Navarro, Manuel Van Domselaar, Ana Gutiérrez-Casbas, Inmaculada Alonso-Abreu, Manuel Barreiro-de Acosta, Luis Fernández-Salazar, Marisa Iborra, María Dolores Martín-Arranz, Natalia García-Morales, Jordi Guardiola, Abdel Bouhmidi-Assakali, María Esteve, Carmen Muñoz-Villafranca, Iago Rodríguez-Lago, Daniel Ceballos, Iván Guerra, Miriam Mañosa, Ignacio Marín-Jiménez, Isabel Vera-Mendoza, Ana Garre, María Chaparro, Javier P. Gisbert","doi":"10.1111/apt.70172","DOIUrl":null,"url":null,"abstract":"The EXIT trial found no difference in sustained remission at 12 months between inflammatory bowel disease (IBD) patients in remission who withdrew anti-TNF therapy [withdrawal arm (WA)] and those who maintained treatment [maintenance arm (MA)].","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"12 1","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU\",\"authors\":\"María José Casanova, Cristina Rubín de Célix, Sabino Riestra, Alfredo J. Lucendo, José Manuel Benítez, Mercè Navarro-Llavat, Jesús Barrio, Víctor J. Morales-Alvarado, Montserrat Rivero, David Busquets, Eduardo Leo-Carnerero, Oscar Nantes-Castillejo, Pablo Navarro, Manuel Van Domselaar, Ana Gutiérrez-Casbas, Inmaculada Alonso-Abreu, Manuel Barreiro-de Acosta, Luis Fernández-Salazar, Marisa Iborra, María Dolores Martín-Arranz, Natalia García-Morales, Jordi Guardiola, Abdel Bouhmidi-Assakali, María Esteve, Carmen Muñoz-Villafranca, Iago Rodríguez-Lago, Daniel Ceballos, Iván Guerra, Miriam Mañosa, Ignacio Marín-Jiménez, Isabel Vera-Mendoza, Ana Garre, María Chaparro, Javier P. Gisbert\",\"doi\":\"10.1111/apt.70172\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The EXIT trial found no difference in sustained remission at 12 months between inflammatory bowel disease (IBD) patients in remission who withdrew anti-TNF therapy [withdrawal arm (WA)] and those who maintained treatment [maintenance arm (MA)].\",\"PeriodicalId\":121,\"journal\":{\"name\":\"Alimentary Pharmacology & Therapeutics\",\"volume\":\"12 1\",\"pages\":\"\"},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2025-05-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alimentary Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/apt.70172\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.70172","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU
The EXIT trial found no difference in sustained remission at 12 months between inflammatory bowel disease (IBD) patients in remission who withdrew anti-TNF therapy [withdrawal arm (WA)] and those who maintained treatment [maintenance arm (MA)].
期刊介绍：
Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
